LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Lexaria Bioscience Corp.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERLEXX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / LEXX COVERAGE

What’s moving Lexaria Bioscience Corp. now

Current reporting with the operating signal separated from the noise.

01
TradingView

Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock Split - SEC Filing

Investors are testing whether Lexaria Bioscience Corp.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Lexaria Bioscience Corp.: Lexaria Announces Effective Date for Reverse Stock Split

Lexaria Bioscience Corp.: Lexaria Announces Effective Date for Reverse Stock Split

Investors are testing whether Lexaria Bioscience Corp.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
TradingKey

LEXX|Lexaria Bioscience Corp|Price:0.505|Chg%:-0.025

The story matters when it changes Lexaria Bioscience Corp.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Lexaria Bioscience Corp.: Lexaria Updates Business Development

Lexaria Bioscience Corp.: Lexaria Updates Business Development

The story matters when it changes Lexaria Bioscience Corp.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

The story matters when it changes Lexaria Bioscience Corp.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

The story matters when it changes Lexaria Bioscience Corp.’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
07
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

The story matters when it changes Lexaria Bioscience Corp.’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
PRIMARY DOCUMENTS / SEC EDGAR

Latest LEXX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-13 · Period 2026-05-31SEC ↗10-QQuarterly financial reportFiled 2026-04-13 · Period 2026-02-28SEC ↗10-KAnnual financial reportFiled 2025-11-28 · Period 2025-08-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-29SEC ↗8-KMaterial company eventFiled 2026-02-06 · Period 2026-02-04SEC ↗8-KMaterial company eventFiled 2026-01-28 · Period 2026-01-27SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-12-10 · Period 2026-01-27SEC ↗4Official SEC filingFiled 2026-03-18 · Period 2026-03-17SEC ↗
EARNINGS / QUARTERLY TRACKER

Lexaria Bioscience Corp., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.